Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Limited informed the BSE that it has received a certificate from Venture Capital and Corporate Investments Private Limited, acting as its registrar and share transfer agent, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter and half year ended September 30, 2026.

Pharmaids Pharmaceuticals Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the quarter and half year ended September 30, 2026, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Pharmaids Pharmaceuticals Limited will hold a board meeting on Wednesday, August 12, 2026, to consider and approve the unaudited financial results (standalone & consolidated) for the quarter ended June 30, 2026, according to a regulatory filing with the BSE Limited. The company closed its trading window for securities dealings from July 01, 2026, and it will reopen 48 hours after the financial results are declared.

Net Loss of Pharmaids Pharmaceuticals reported to Rs 1.81 crore in the quarter ended March 2026 as against net loss of Rs 3.94 crore during the previous quarter ended March 2025. Sales rose 50.52% to Rs 7.18 crore in the quarter ended March 2026 as against Rs 4.77 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 11.72 crore in the year ended March 2026 as against net loss of Rs 10.78 crore during the previous year ended March 2025. Sales rose 43.34% to Rs 27.88 crore in the year ended March 2026 as against Rs 19.45 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales7.184.77 51 27.8819.45 43 OPM %-4.74-81.76 --48.53-65.55 - PBDT-0.89-4.84 82 -16.74-14.74 -14 PBT-1.37-5.46 75 -18.76-17.18 -9 NP-1.81-3.94 54 -11.72-10.78 -9 Powered by Capital Market - Live

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Pharmaids Pharmaceuticals announced the disinvestment/sale of shareholding in Siri Labvivo Diet (the company's step-down subsidiary) by Adita Bio Sys (the company's material subsidiary). Consequent to the completion of the above transaction, Siri Labvivo Diet has ceased to be a subsidiary of Adita Bio Sys and accordingly, has also ceased to be a step-down subsidiary of the Company with effect from 27 March 2026. Powered by Capital Market - Live

Net Loss of Pharmaids Pharmaceuticals reported to Rs 2.48 crore in the quarter ended December 2025 as against net loss of Rs 1.93 crore during the previous quarter ended December 2024. Sales rose 15.29% to Rs 5.43 crore in the quarter ended December 2025 as against Rs 4.71 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales5.434.71 15 OPM %-46.22-61.36 - PBDT-3.15-3.36 6 PBT-3.62-4.00 10 NP-2.48-1.93 -28 Powered by Capital Market - Live

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live

Net Loss of Pharmaids Pharmaceuticals reported to Rs 2.48 crore in the quarter ended September 2025 as against net loss of Rs 1.93 crore during the previous quarter ended September 2024. Sales rose 64.31% to Rs 8.61 crore in the quarter ended September 2025 as against Rs 5.24 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales8.615.24 64 OPM %-61.79-45.99 - PBDT-6.18-2.73 -126 PBT-6.65-3.34 -99 NP-2.48-1.93 -28 Powered by Capital Market - Live

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live